Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma

被引：0

作者：

Luc M. Berclaz ^{[1
]}

Anton Burkhard-Meier ^{[2
]}

Axel Lechner ^{[1
]}

Michael Völkl ^{[3
]}

Sinan E. Güler ^{[1
]}

Sultan Abdel-Rahman ^{[1
]}

Sina Mansoorian ^{[1
]}

Wolfgang G. Kunz ^{[4
]}

Thomas Knösel ^{[5
]}

Martin Canis ^{[6
]}

Michael von Bergwelt-Baildon ^{[3
]}

Rolf D. Issels ^{[1
]}

Dorit Di Gioia ^{[2
]}

Lars H. Lindner ^{[1
]}

机构：

[1] University Hospital,Department of Internal Medicine III

[2] LMU Munich,Deparment of Otorhinolaryngology

[3] German Cancer Consortium (DKTK),Department of Radiation Oncology

[4] Partner Site Munich,Department of Radiology

[5] University Hospital,Institute of Pathology

[6] LMU Munich,undefined

[7] University Hospital,undefined

[8] LMU Munich,undefined

[9] University Hospital,undefined

[10] LMU Munich,undefined

[11] LMU Munich,undefined

来源：

Cancer Immunology, Immunotherapy | / 74卷 / 6期

关键词：

Immunotherapy; Immune checkpoint inhibitors; Head and neck cancer; Regional hyperthermia;

D O I：

10.1007/s00262-025-04029-9

中图分类号：

学科分类号：

摘要：

We report a long-lasting response to the immune checkpoint inhibitor nivolumab in combination with regional hyperthermia (RHT) in a patient with recurrent metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and negative programmed death ligand 1 (PD-L1) expression. Treatment was well tolerated with no local side effects. Tumor-related symptoms in the orbital and masticator area gradually decreased under treatment with nivolumab and RHT. Over the course of treatment, magnetic resonance imaging (MRI) showed a local tumor control in the heated tumor areas, while metastatic lesions developed in areas outside of the RHT field. This is the first case report demonstrating the feasibility and clinical potential of the addition of RHT in this patient collective with poor outcomes and low response rates to immune checkpoint inhibitors. RHT might be an additional tool to activate an immunogenic milieu responsive to immune checkpoint inhibitors.

引用

共 50 条

[31] Comparison of patient populations identified by different PD-L1 assays in head and neck squamous cell carcinoma (HNSCC)
Scott, M.
Wildsmith, S.
Ratcliffe, M.
Al-Masri, H.
Scorer, P. W.
Barker, C.
Rebelatto, M. C.
Walker, J.
ANNALS OF ONCOLOGY, 2018, 29
[32] Effect of performance status on the therapeutic effect of nivolumab in recurrent or metastatic squamous cell carcinoma of the head and neck
Nishimura, Ari
Ishida, Chie
Tanaka, Akihisa
Kimura, Takahiro
Yoshii, Yumi
Uemura, Hirokazu
Takeda, Masayuki
Kitahara, Tadashi
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2024, : 2071 - 2076
[33] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Economopoulou, Panagiota
Kotsantis, Ioannis
Papaxoinis, George
Gavrielatou, Niki
Anastasiou, Maria
Pantazopoulos, Anastasios
Kavourakis, George
Gkolfinopoulos, Stavros
Panayiotides, Ioannis
Delides, Alexandros
Psyrri, Amanda
ORAL ONCOLOGY, 2020, 111
[34] Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Yamashita, G. A., I
Okamoto, I. S. A. K. U.
Ito, T. A. T. S. U. Y. A.
Tokashiki, K. U. N. I. H. I. K. O.
Okada, T. A. K. U. R. O.
Tsukahara, K. I. Y. O. A. K. I.
ANTICANCER RESEARCH, 2023, 43 (08) : 3679 - 3683
[35] Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma
Becherini, Carlotta
Banini, Marco
Desideri, Isacco
Salvestrini, Viola
Caprara, Luisa
Scotti, Vieri
Ganovelli, Michele
Morelli, Ilaria
Romei, Andrea
Livi, Lorenzo
Bonomo, Pierluigi
JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
[36] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply
Harrington, Kevin J.
Haddad, Robert
JAMA ONCOLOGY, 2024, 10 (01) : 144 - 145
[37] PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the US
Hanna, Glenn J.
Zheng, Dandan
Gao, Wei
Hair, Gleicy M.
Ai, Lei
Song, Yan
Lerman, Nati
Bidadi, Behzad
Zion, Abigail
Zou, Lin
Tang, Yuexin
Wang, Liya
Merchant, Sanjay
Black, Christopher M.
ORAL ONCOLOGY, 2025, 161
[38] Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma
Tsujikawa, Takahiro
Ohno, Kazuchika
Morita, Kei-ichi
Saburi, Sumiyo
Mitsuda, Junichi
Yoshimura, Kanako
Kimura, Alisa
Morimoto, Hiroki
Ogi, Hiroshi
Shibata, Saya
Akashi, Takumi
Kurata, Morito
Imoto, Issei
Shimizu, Yasushi
Kano, Satoshi
Watanabe, Akihito
Yamazaki, Tomoko
Asada, Yukinori
Hayashi, Ryuichi
Saito, Yuki
Ozawa, Hiroyuki
Tsukahara, Kiyoaki
Oridate, Nobuhiko
Sano, Daisuke
Horii, Arata
Ueki, Yushi
Maruo, Takashi
Mukoyama, Nobuaki
Hanai, Nobuhiro
Fukusumi, Takahito
Iwai, Hiroshi
Fujisawa, Takuo
Fujii, Takashi
Nibu, Ken-ichi
Iwae, Shigemichi
Ueda, Tsutomu
Chikuie, Nobuyuki
Yasumatsu, Ryuji
Matsuo, Mioko
Umeno, Hirohito
Ono, Takeharu
Masuda, Muneyuki
Toh, Satoshi
Itoh, Kyoko
Hirano, Shigeru
Asakage, Takahiro
FRONTIERS IN IMMUNOLOGY, 2024, 15
[39] Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines
Fiedler, Mathias
Schulz, Daniela
Piendl, Gerhard
Brockhoff, Gero
Eichberger, Jonas
Menevse, Ayse-Nur
Beckhove, Philipp
Hautmann, Matthias
Reichert, Torsten E.
Ettl, Tobias
Bauer, Richard J.
EXPERIMENTAL CELL RESEARCH, 2020, 396 (01)
[40] Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
Ferris, Robert L.
Gooding, William E.
Chiosea, Simion I.
Duvvuri, Umamaheswar
Kim, Seungwon
Kubik, Mark
Sridharan, Shaum
Fenton, Moon Jung
Skinner, Heath Devin
Kelly, Zahra Rahman
Li, Housaiyin
Vujanovic, Lazar
Zandberg, Dan Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →